Posted by SLS on June 29, 2021, at 16:07:59
In reply to Re: Short-Course Zuranolone Looks Promising for MDD, posted by linkadge on June 22, 2021, at 15:16:46
> Very cool. Nice to see some different mechanisms.
>
> LinkadgeI had been looking at zuranolone (SAGE-217) beginning in 2019 after the I.V. post-partum drug, brexanolone (Zulresso), was approved. Both drugs were developed by the same drug company as part of a series of related compounds. Zuranolone was the second of the series to be chosen for clinical trials. Hopefully, I will never need it. It was going to be the very next thing I would have tried had I not found success with my current treatment.
Positive allosteric modulators bind to a secondary site on a receptor such that it changes the shape of it. This makes the GABA-A receptor more sensitive to GABA.
These new drugs are related to the progesterone-like substance, allopregnanolone
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.The only thing necessary for the triumph of evil is that good men do nothing.
poster:SLS
thread:1115627
URL: http://www.dr-bob.org/babble/20210418/msgs/1115677.html